jump to content jump to footer

Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Video Clinical Trials Standardized Reading Procedures Therapy Response Assessment Structured Reporting

Related Resources

Medical professional reviewing patient's MRI images on computer monitor with patient in MRI machine in background.
TGSE-BLADE demonstrated significantly reduced geometric distortion and artifacts caused by intracranial air, enabling more accurate detection of ischemic changes and improving diagnostic confidence in early postoperative MRI.
Postoperative Brain MRI After Tumor Resection: Reducing Artifacts and Improving Diagnostic Accuracy
Postoperative MRI after brain tumor surgery is often affected by artifacts caused by intracranial air, limiting reliable image interpretation. A…
Centralized Management for Clinical Trial Communications and Workflows
Requests for radiological clinical trial evaluations frequently rely on fragmented methods such as emails, phone calls, and spreadsheets. This…
mint Lesion usage during a clinical trial read, featuring the TGRM export tool.
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer
For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…